The AVEN Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line, with disrupted AVEN expression. This loss-of-function model, generated via CRISPR/Cas9-mediated gene disruption, consists of a pool of cells carrying heterogeneous editing events that eliminate functional AVEN protein. The polyclonal format bypasses clonal selection biases, preserving genetic diversity and providing a robust system for studying AVEN biology.
The HT29 host cell line is an established epithelial model from a 44-year-old Caucasian female with colorectal adenocarcinoma. These adherent cells retain key features of primary colorectal tumors, including dysregulated apoptosis and oncogenic signaling, making HT29 a widely used tool for investigating tumor survival, drug sensitivity, and epithelial cancer biology.
AVEN (Apoptosis inhibitor v-erbA-related gene) is a critical inhibitor of intrinsic apoptosis. It directly interacts with Apaf-1 and Bcl-2, blocking procaspase-9 (CASP9) activation and suppressing mitochondrial apoptotic signaling. AVEN activity is transcriptionally regulated by E2F1 and TP53, and modulated by DNA damage kinases ATM and ATR, as well as FANCD2. AVEN forms complexes with FANCD2 and Apaf-1, linking DNA repair and cell death pathways. Downstream, AVEN influences caspase-9 activation and mitochondrial permeabilization, with Bcl-2 as a key counterplayer.
In HT29 colorectal cancer cells, AVEN knockout is expected to sensitize cells to apoptosis induced by DNA-damaging agents. HT29 cells harbor TP53 mutations and rely on alternative survival mechanisms, making AVEN a critical factor. Disrupting AVEN can expose vulnerabilities to chemotherapeutics like 5-fluorouracil and oxaliplatin, and enhance radiation efficacy. This polyclonal knockout model is thus a physiologically relevant system to dissect apoptosis evasion in colorectal tumors and identify synthetic lethal interactions.
Researchers can apply this model to study apoptosis resistance, screen pro-apoptotic compounds, and assess chemosensitivity. Assays include Western blotting for cleaved caspase-3 and PARP, flow cytometry with annexin V/PI, viability assays (MTT, CellTiter-Glo), colony formation, and ??H2AX foci analysis to probe DNA damage. Co-immunoprecipitation can confirm disrupted Aven-Apaf-1 binding. For further details, contact Ascent Research.
